Dies ist eine Übersichtsseite mit Metadaten zu dieser wissenschaftlichen Arbeit. Der vollständige Artikel ist beim Verlag verfügbar.
Finding the optimal regimen for short-term daily recombinant human erythropoietin treatment for blood-saving purpose in patients undergoing unilateral primary total hip arthroplasty: a double-blinded randomized placebo-controlled trial
7
Zitationen
5
Autoren
2022
Jahr
Abstract
Daily small-dose of subcutaneous rhEPO administered from 5 days before THA could significantly decrease perioperative blood loss and improve postoperative Hb levels, without increasing risks of complications, when compared with the application of rhEPO from 3 days before THA or from the day of surgery. However, surgeons should choose the regimen individually according to different patients' personal circumstances.
Ähnliche Arbeiten
A Multicenter, Randomized, Controlled Clinical Trial of Transfusion Requirements in Critical Care
1999 · 5.201 Zit.
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial
2010 · 3.231 Zit.
Transfusion of Plasma, Platelets, and Red Blood Cells in a 1:1:1 vs a 1:1:2 Ratio and Mortality in Patients With Severe Trauma
2015 · 2.433 Zit.
Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma
2020 · 2.420 Zit.
A Multicenter, Randomized, Controlled Clinical Trial of Transfusion Requirements in Critical Care
1999 · 2.045 Zit.